IMAB Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (17 birž. 2024 @ 23:00):
Our systems believe the stock currently is undervalued by -1.07% compare to its pairs and should correct upwards.

Stats
Šios dienos apimtis	145 841
Vidutinė apimtis	247 506
Rinkos kapitalizacija	140.18M
EPS	CNY-1.240 ( Q4 \| 2024-04-30 )
Kita pelno data	( CNY0 ) 2024-08-15
Last Dividend	CNY0 ( N/A )
Next Dividend	CNY0 ( N/A )
P/E	-0.730 (Sector) 42.63 (Industry) 24.32
ATR14	CNY0.00400 (0.22%)

AADI -3.55%

ABCL -5.26%

ABCM 0.04%

ABEO -1.31%

ABIO -1.53%

ABOS -5.30%

ABSI -14.32%

ABUS -2.55%

ABVX -0.22%

ACAD -0.47%

ACER -17.95%

ACET -2.22%

ACGN 1.29%

ACHL 0.23%

ACHV 1.63%

ACIU -4.23%

ACLX -1.21%

ACRV -5.10%

ACST 0.62%

ACXP -0.42%

ADAG -5.64%

ADAP -7.23%

ADGI 0.87%

ADIL -2.29%

ADMA -1.79%

ADPT 0.32%

ADTX -7.69%

ADVM -3.94%

ADXN -6.11%

AEON 11.51%

AEZS -5.44%

AFMD -5.07%

AGEN -7.50%

AGIO -3.45%

AGLE 6.66%

AGTC 0.00%

AIKI 0.85%

AIMDW 53.45%

AKBA -1.87%

AKRO -4.46%

AKTX -6.33%

AKUS 0.00%

ALBO 0.00%

ALDX -1.34%

ALEC -2.35%

ALGS -5.76%

ALKS 2.08%

ALLK 0.86%

ALLO -2.13%

ALLR -3.01%

ALNA 3.16%

ALNY -1.93%

ALPN 0.00%

ALPX 0.00%

ALRN -0.31%

ALT -3.11%

ALVR -4.43%

ALXN 0.00%

ALXO -8.32%

ALZN -12.01%

AMRN -2.58%

AMTI -3.13%

ANAB -1.64%

ANEB -5.58%

ANGN 0.00%

ANIX -0.38%

ANL 0.61%

ANNX -4.63%

ANPC -3.15%

APGE -5.23%

APGN 8.48%

APGNW 30.65%

APLM -4.73%

APLS -3.98%

APLT -4.36%

APM 1.33%

APOP 0.38%

APRE 2.44%

APTO -3.96%

APTX 3.17%

APVO -20.53%

ARAV -13.39%

ARCT -9.26%

ARDS 20.48%

ARDX -0.94%

ARGX -2.25%

ARNA 0.00%

ARPO -0.90%

ARQT -7.76%

ARTL -0.38%

ARTLW 9.80%

ARVN -2.84%

ARWR -2.86%

ASLN -12.17%

ASMB -1.49%

ASND -2.39%

ATAI -2.19%

ATHA 2.36%

ATHE -1.61%

ATHX -33.50%

ATNF 15.09%

ATOS -4.17%

ATRA -16.93%

ATXI -1.66%

ATXS -3.50%

AUPH -1.95%

AURA 0.96%

AUTL -4.22%

AVBP -1.02%

AVEO 0.00%

AVIR -2.22%

AVRO 2.10%

AVTE -93.30%

AVTX 4.08%

AVXL -1.06%

AXLA 0.00%

AXSM 3.22%

AYLA 0.00%

AZRX 2.07%

BBI 2.17%

BBIO -2.26%

BCAB -1.89%

BCDA -2.05%

BCDAW -33.33%

BCEL -1.32%

BCLI -8.47%

BCRX 1.13%

BCTX 4.96%

BCTXW 0.00%

BCYC -4.33%

BDRX 1.89%

BDTX -8.38%

BEAM -3.38%

BFRA -2.91%

BGNE -1.97%

BIOR -10.12%

BIVI 0.41%

BLCM -6.68%

BLI -5.88%

BLPH -0.79%

BLRX -3.79%

BLTE -0.72%

BLU 0.03%

BLUE -0.77%

BMEA -9.75%

BMRN 1.81%

BNOX 1.64%

BNTC 2.46%

BNTX -3.95%

BOLD -5.95%

BOLT -0.82%

BPMC -1.59%

BPTH 10.65%

BPTS -13.47%

BRNS -6.63%

BRTX 20.00%

BTAI -2.92%

BTTX -7.50%

BTX 0.05%

BVXV 0.74%

BXRX 7.39%

BYSI 6.06%

CABA -12.20%

CADL -0.96%

CALA 60.00%

CALC -1.62%

CALT 0.03%

CAPR -4.06%

CARA -27.26%

CARM -9.65%

CASI -8.04%

CATB -6.97%

CBAY 0.03%

CBIO -2.65%

CBLI -7.31%

CBUS 3.07%

CCCC -5.48%

CCXI 0.00%

CDAK 0.00%

CDIO -1.51%

CDIOW -23.08%

CDMO 5.72%

CDMOP 0.04%

CDT -6.11%

CDTTW -47.71%

CDTX -6.32%

CDXC -0.67%

CDXS -2.30%

CELC -2.79%

CELU -2.19%

CELUW -9.52%

CERC -1.68%

CERE -0.16%

CERO -7.87%

CEROW -44.78%

CFRX -27.95%

CGEM 0.74%

CGEN -5.31%

CGON -2.68%

CGTX 0.92%

CHMA -6.00%

CHRS -2.96%

CINC 0.00%

CING -1.09%

CINGW -48.24%

CKPT -4.25%

CLBS -16.75%

CLDX 0.69%

CLGN 1.19%

CLLS -4.89%

CLNN -2.48%

CLNNW -41.25%

CLRB -9.94%

CLSD -0.84%

CLSN -0.68%

CLVS 0.00%

CMMB -24.79%

CMND 1.83%

CMPI 0.00%

CMPX 5.41%

CMRA 0.40%

CMRAW 33.33%

CMRX 1.44%

CNCE 0.00%

CNSP 3.94%

CNST 0.00%

CNTA -6.39%

CNTB 3.13%

CNTX -1.02%

COCP -0.16%

COEPW -0.66%

COGT 4.45%

CORT -1.31%

COYA -6.11%

CPRX -0.40%

CRBP -11.76%

CRBU -2.23%

CRDF -1.11%

CRGX -4.78%

CRIS 1.11%

CRNX -1.37%

CRSP -2.79%

CRTX 2.63%

CRVO -1.89%

CRVS -5.39%

CSBR 1.19%

CTCX -8.04%

CTIC 0.06%

CTMX -0.72%

CTNM 0.00%

CTXR -1.50%

CUE -1.47%

CVAC -5.18%

CVKD 3.18%

CWBR -2.55%

CYAD -12.96%

CYCC -3.55%

CYCCP -1.79%

CYCN 6.00%

CYT -2.27%

CYTK -2.13%

CYTO 2.48%

DARE -3.31%

DAWN -4.60%

DBTX -0.81%

DBVT 1.01%

DFFN 10.28%

DICE 0.06%

DMAC -0.42%

DNLI -1.21%

DNTH -2.85%

DOMH 1.99%

DRMA 0.00%

DRMAW 0.00%

DRNA 0.00%

DRTS -1.32%

DRTSW 1.01%

DRUG 0.00%

DSGN 2.97%

DTIL -2.07%

DYAI -5.29%

EARS -1.77%

EDIT 0.20%

EDSA 1.04%

EFTR -3.13%

EFTRW -0.26%

EIGR 0.00%

ELAB 1.44%

ELDN -6.93%

ELEV -7.89%

ELOX -12.50%

ELTX -2.33%

ELVN -0.65%

ELYM -13.05%

ENGN -3.89%

ENGNW -7.06%

ENLV -3.47%

ENOB 1.79%

ENSC -0.55%

ENTA -6.00%

ENTO -2.80%

ENTX 0.00%

ENVB -4.64%

EPIX -8.75%

EPRX -0.19%

EPZM 0.00%

EQ 0.50%

EQRX -2.09%

EQRXW 0.00%

ERAS -7.83%

ERNA 2.60%

ERYP 1.30%

ESLA -6.38%

ESLAW -9.25%

ETNB 1.03%

ETON -5.90%

ETTX 0.00%

EVAX -19.54%

EVGN -2.14%

EVLO 50.00%

EWTX -0.80%

EXAI 1.19%

EXEL 0.18%

EYEG -0.43%

EYEN 1.57%

EYPT -3.94%

FATE -1.11%

FBIO 1.60%

FBIOP -1.05%

FBLG -5.34%

FBRX -7.46%

FDMT 0.72%

FENC 0.74%

FGEN -5.36%

FHTX 9.52%

FIXX 0.77%

FMTX 0.00%

FNCH -6.25%

FOLD -0.99%

FREQ 4.76%

FRLN 0.15%

FRTX -0.54%

FSTX 0.00%

FTRE 0.38%

FULC -6.04%

FUSN 0.00%

FWBI 4.59%

FWP 0.00%

GALT -4.58%

GANX 6.45%

GBIO 6.57%

GBT 0.01%

GDTC 2.16%

GERN -4.11%

GHRS 3.42%

GLMD -6.66%

GLPG 1.18%

GLSI 18.16%

GLTO -4.90%

GLUE -4.18%

GLYC -9.70%

GMAB -1.57%

GMDA 0.00%

GMTX 0.00%

GNCA -85.71%

GNFT 0.14%

GNLX 1.27%

GNPX 1.84%

GNTA -0.60%

GOSS 0.02%

GOVX -7.50%

GOVXW -24.72%

GPCR 0.85%

GRAY -10.80%

GRCL 0.05%

GRNA -0.03%

GRNAW 8.91%

GRPH -2.75%

GRTS -2.71%

GRTX -4.26%

GTHX -3.96%

GUTS -3.90%

GXGXW 41.67%

GYRE 4.44%

HALO 0.32%

HARP 0.09%

HCWB -9.73%

HEPA -6.36%

HGEN -84.62%

HILS 5.66%

HLVX 1.33%

HOOK -4.04%

HOTH -3.73%

HOWL 3.99%

HRMY 1.10%

HRTX -10.42%

HSTO 62.16%

HUMA -12.20%

HUMAW -5.97%

IBRX -2.18%

ICCC 2.84%

ICPT 0.21%

ICU 1.30%

ICUCW -10.39%

ICVX -0.91%

IDRA -23.04%

IDYA -1.44%

IFRX -3.21%

IGMS 0.41%

IKNA -0.57%

IKT 8.90%

IMAB -1.09%

IMCR -3.82%

IMGN 0.02%

IMGO 0.00%

IMMP -0.74%

IMMX -0.49%

IMNM -11.86%

IMNN -1.80%

IMPL -27.27%

IMRA 15.96%

IMRN -2.78%

IMRX 1.66%

IMTX -0.08%

IMTXW -2.70%

IMUX -4.20%

IMV 0.00%

IMVT 3.08%

INAB -8.26%

INBX -9.62%

INCY 0.93%

INDP 7.98%

INFI -52.38%

INKT -1.05%

INM -2.58%

INMB -2.47%

INO -1.65%

INSM 1.22%

INTS -5.63%

INVA 1.57%

INZY -2.95%

IOBT -6.11%

IONS 0.27%

IOVA -0.98%

IPA 0.48%

IPHA -10.64%

IPSC 0.64%

IRON -3.05%

ISEE 0.38%

ITOS -6.04%

ITRM -1.74%

IVA -10.10%

IVVD -6.96%

JAGX -6.67%

JANX -4.57%

JAZZ 1.43%

JNCE 0.00%

JSPR -2.80%

JSPRW 2.33%

JUNS 0.00%

JUNSW 0%

KA 4.11%

KALV -2.07%

KDNY 0.22%

KMPH -0.34%

KNSA -1.28%

KNTE -0.38%

KOD -4.27%

KPRX -21.08%

KPTI 1.69%

KRBP 4.17%

KRON -3.70%

KROS -9.68%

KRRO -16.54%

KRTX 0.03%

KRYS -0.04%

KTRA -2.35%

KTTA -2.85%

KTTAW 8.62%

KURA -0.62%

KYMR -4.42%

KYTX -17.21%

KZIA -1.29%

KZR -2.71%

LABP 0.57%

LBPH 1.67%

LBPS 0.00%

LBPSW 14.81%

LEGN -2.24%

LENZ -0.54%

LEXX -5.18%

LEXXW -9.42%

LGND 0.72%

LGNDV 0.00%

LGVN -24.76%

LIAN 0.00%

LIFE 2.70%

LIPO -1.23%

LIXT 0.40%

LIXTW 27.74%

LJPC -0.32%

LMNL 0.12%

LOGC 2.76%

LPCN 12.64%

LPTX -1.90%

LQDA 3.01%

LRMR -14.91%

LSTA -4.97%

LTRN -8.57%

LUMO -2.95%

LVTX -9.52%

LXEO -6.50%

LXRX -5.49%

LYEL -8.05%

LYRA -8.37%

MACK 0.00%

MBIO 476.92%

MBRX -4.83%

MCRB -5.28%

MDGL -0.31%

MDNA -13.16%

MDWD 1.00%

MDXG 0.59%

MEIP 1.41%

MESO -0.55%

MGNX -4.03%

MGTA -7.74%

MGTX -2.23%

MGX -24.14%

MIRM 27.31%

MIRO 0.59%

MIST -1.42%

MITO 0.00%

MLEC -4.55%

MLECW 9.20%

MLND -5.36%

MLTX -2.99%

MLYS -3.02%

MNKD -1.04%

MNMD -3.36%

MNOV 0.00%

MNPR -8.51%

MOLN 8.81%

MOR 0.88%

MORF -1.25%

MREO 0.00%

MRKR 16.59%

MRNA -1.52%

MRNS -1.02%

MRSN -1.45%

MRTX -0.17%

MRUS -1.38%

MRVI -3.99%

MTCR -1.29%

MTEM 1.54%

MTP -18.50%

MURA 2.17%

MYMD 4.19%

NAMS -7.03%

NAMSW -7.61%

NAUT 0.00%

NBRV 0.71%

NBSE -1.56%

NBTX 4.77%

NCNA -1.64%

NERV 8.96%

NEXI 0.00%

NGM -1.28%

NGNE -6.08%

NKGN -4.44%

NKGNW 39.76%

NKTR 0.00%

NKTX -5.66%

NLSP 30.09%

NLSPW -16.67%

NMRA -4.09%

NMTR -42.97%

NOVN -24.84%

NRBO 0.45%

NRIX 0.72%

NRSN -3.82%

NRSNW 6.50%

NRXP 0.99%

NRXPW -15.65%

NRXS -6.06%

NTBL 13.82%

NTEC -12.45%

NTHI 0%

NTLA 0.08%

NTRBW -6.25%

NUVL -0.77%

NVAX -2.43%

NVCT 1.18%

NVIV -34.28%

NXTC -10.63%

NYMX -0.05%

OABI 0.95%

OABIW 13.46%

OBIO 0.88%

OBSV 0.00%

OCEA 10.64%

OCGN -5.63%

OCS -1.09%

OCUL -4.35%

OCUP 1.82%

ODT -4.27%

OKYO 0.00%

OLMA -3.96%

OMER -0.49%

OMGA -8.37%

ONCO 12.54%

ONCR -3.08%

ONCS 31.87%

ONCT -0.12%

ONCY -0.98%

ONTX -0.47%

ONVO 0.62%

OPNT 0.00%

OPT -5.51%

ORGS -1.72%

ORIC -0.67%

ORMP -0.44%

ORPH 0.00%

ORTX 0.30%

OSMT -1.77%

OTIC -92.64%

OTLK -1.43%

OVID -76.00%

OYST 0.00%

PALI 0.86%

PASG -3.81%

PBLA 9.76%

PBM -0.02%

PBYI 2.89%

PCSA 5.71%

PCVX -1.45%

PDSB -4.13%

PEPG 0.70%

PGEN 0.00%

PHAR 2.17%

PHAS 0.00%

PHAT 3.08%

PHIO 4.14%

PHIOW 36.47%

PHVS -0.53%

PHXM -5.20%

PIRS -5.64%

PKBO 0.00%

PKBOW 999 900.00%

PLRX -5.08%

PLUR 0.00%

PMN -5.59%

PMVP -1.20%

PNT 0.16%

PPBT -11.48%

PRAX -6.21%

PRDS 0.93%

PRLD 0.77%

PROG -3.47%

PROK 6.96%

PRQR -3.41%

PRTA -0.20%

PRTC -0.72%

PRTG -1.96%

PRTK 1.83%

PRVB 0.00%

PSTI -2.91%

PSTV 0.00%

PSTX 1.81%

PTCT -1.14%

PTE -0.82%

PTGX -2.76%

PTIXW 2.50%

PULM 3.72%

PXMD -1.92%

PYPD -0.36%

PYXS -3.43%

QLGN -11.72%

QNCX 0.00%

QNRX -10.97%

QSI -2.92%

QSIAW 0.00%

QTTB 3.82%

QURE -4.09%

RAIN -1.63%

RANI -5.46%

RAPT -0.30%

RARE 1.92%

RCKT -3.02%

REGN 0.85%

RENB -3.05%

REPL -6.63%

RETA 0.02%

REUN -0.89%

REVB 1.36%

REVBU 3.46%

REVBW 25.20%

RGLS -1.66%

RGNX -6.20%

RIGL -2.79%

RLAY -3.01%

RLMD -0.33%

RLYB -6.15%

RNA -0.10%

RNAC -14.55%

RNAZ -5.83%

RNXT 14.41%

ROIV 0.28%

ROIVW 4.56%

RPHM -0.60%

RPRX -1.15%

RPTX 0.00%

RUBY 2.70%

RVLP -32.05%

RVMD -3.94%

RVMDW -23.93%

RVNC -0.71%

RVPH -0.68%

RVPHW 11.54%

RXDX 0.09%

RXRX 1.19%

RYTM -3.76%

RYZB 0.02%

RZLT -2.53%

SABS 3.17%

SABSW -32.14%

SAGE -6.08%

SANA -1.32%

SAVA 0.81%

SAVAW 0.00%

SBBP 1.52%

SBTX 1.03%

SCNI 60.46%

SCPH -1.69%

SCPS 0.00%

SEEL -4.62%

SEER -3.37%

SELB -8.00%

SESN 7.29%

SGEN -0.07%

SGMO -17.30%

SGMT 1.93%

SGTX -2.56%

SIOX 22.63%

SLDB -5.44%

SLGL -2.22%

SLN -1.55%

SLNO 0.19%

SLRX 2.89%

SLS -16.67%

SMMT -5.84%

SNDX -1.14%

SNGX -5.91%

SNPX -3.97%

SONN -4.75%

SPPI -0.49%

SPRB 0.49%

SPRC -3.16%

SPRO -5.88%

SRNE 20.00%

SRPT -4.89%

SRRA 0.00%

SRRK -7.09%

SRZN -1.70%

STAB 0.00%

STOK -4.00%

STRO -7.51%

STSA 0.00%

STTK -19.55%

SURF -0.93%

SVRA -5.15%

SWTX -4.88%

SYBX -0.63%

SYRS -4.83%

TALS -0.73%

TARA -0.78%

TARS -6.91%

TBPH -0.59%

TCBP -8.64%

TCDA 0.00%

TCON 6.35%

TCRR 0.00%

TCRT 1.05%

TCRX -11.43%

TECH -1.40%

TENX -3.43%

TERN -2.93%

TFFP 0.52%

TGTX 0.12%

THRX 0.12%

TIL -2.06%

TLC 0.00%

TLSA 5.78%

TNGX 5.04%

TNXP -2.61%

TNYA -1.79%

TPST 0.34%

TRDA -3.61%

TRVI 2.08%

TRVN -1.88%

TSHA 1.51%

TSVT 3.29%

TTNP 1.45%

TVTX 2.23%

TYRA -8.69%

UBX -4.17%

UNCY 0.22%

URGN -4.79%

UTHR 3.12%

VACC 11.36%

VALN -1.55%

VAXX -0.11%

VBIV -3.61%

VBLT -8.77%

VCEL -1.37%

VCNX -3.70%

VCYT 1.96%

VERA -0.83%

VERU 2.29%

VERV -2.77%

VIGL -2.08%

VINC -4.90%

VIR -5.85%

VIRI 4.95%

VIRX -3.62%

VKTX 0.00%

VLON -13.04%

VNDA 1.76%

VOR 1.74%

VRCA 0.49%

VRDN -1.93%

VRNA 10.04%

VRPX 10.77%

VRTX -1.46%

VSTM 0.00%

VTGN -2.84%

VTVT -0.10%

VTYX -4.51%

VXRT -8.25%

VYGR -2.94%

VYNE 2.16%

VYNT 7.78%

WINT 7.98%

WVE -3.85%

XBIO 6.75%

XBIT -0.33%

XCUR -3.10%

XENE -1.75%

XERS -0.91%

XFOR -2.75%

XLO -6.86%

XLRN 0.00%

XNCR -5.15%

XOMA -4.31%

XOMAO 0.68%

XOMAP -0.14%

XRTX 1.96%

YMAB -1.34%

ZGNX 0.00%

ZIOP -0.88%

ZLAB 1.55%

ZNTL -5.09%

ZSAN 0.00%

Koreliacija (AI algo v.1.1b): Undervalued: -1.07% CNY1.781 paired level. (Algoritmas realiuoju laiku stebi didžiausią koreliaciją turinčių akcijų pokyčius ir suteikia momentinę informaciją)

Tūris Koreliacija

Ilgas: -0.06 (neutral)

Trumpas: -0.28 (neutral)

Signal:(34.389) Neutral

I-Mab Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

I-Mab Koreliacija - Valiuta/Žaliavos

-0.54
( weak negative )

-0.33
( neutral )

0.00
( neutral )

0.03
( neutral )

I-Mab Finansinės ataskaitos

Annual	2023
Pajamos:	CNY27.64M
Bruto pelnas:	CNY27.64M (100.00 %)
EPS:	CNY-16.53

FY	2023
Pajamos:	CNY27.64M
Bruto pelnas:	CNY27.64M (100.00 %)
EPS:	CNY-16.53

FY	2022
Pajamos:	CNY-221.56M
Bruto pelnas:	CNY-248.80M (112.29 %)
EPS:	CNY-31.75

FY	2021
Pajamos:	CNY88.03M
Bruto pelnas:	CNY41.59M (47.25 %)
EPS:	CNY-29.19

Financial Reports:

No articles found.

I-Mab Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

I-Mab

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.